790 Memorial Drive, Suite 2C
About Yumanity Therapeutics
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the estimated patient population of 50 million people worldwide, this remains an area of tremendous unmet medical need with no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address illnesses such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s approach concentrates on correcting the cellular pathologies driven by misfolded proteins and the altered biology and phenotypes driving these diseases.
10 articles with Yumanity Therapeutics
Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease
Yumanity Therapeutics, a company focused on protecting the vitality of the mind by discovering and developing transformative brain-penetrating small molecule drugs to treat neurodegenerative diseases, today announced that the first subject cohort has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of YTX-7739 in healthy volunteers.
Ms. Allen Brings Over 25 Years of Financial Leadership Experience to the Company
7/12/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases, today announced the appointment of accomplished physician, scientist, and industry veteran Richard Peters, M.D., Ph.D., as chief executive officer (CEO).
Yumanity Therapeutics announced that Tony Coles, M.D., chairman and chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 at 2:30 p.m. EDT.
Yumanity Therapeutics Announces Publication of Paper in Cell Reports Detailing a Potential New Therapeutic Target for the Treatment of Parkinson’s Disease
Results suggest inhibiting fatty acid desaturation by blocking the enzyme stearoyl-CoA desaturase (SCD) is a potential therapeutic approach to treating neurodegenerative diseases
Yumanity Therapeutics Announces First Clinical Candidate for the Potential Treatment of Parkinson’s Disease
First-in-Human Trials Planned for the Fourth Quarter of 2019